Infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) remains a burden to the global health system, justifying an elaborate study on the biological and disease progression of such chronic infections. The present cross-sectional study aimed to analyze the stages of the disease progression architecture of the patients infected with HBV and HCV and the important potential biomarkers that could be clinically significant for the disease prognosis. A total of 300 patients were studied with the data showing a reasonable association of the progression of liver fibrosis with increased levels of specific biomarkers such as hepatitis B surface antigen and antibodies against viral load. The statistically significant results showed that patients with high HBsAg, 2.5 ratio pin pointed risk levels for patients suffering from severe liver disease, p less than 0.01, and elevated levels of ALT concentration showed a positive correlation for the degree of the affliction of the disease (p less than 0.05). Understanding the importance of the research results coupled with the somatic nature of the two diseases calls for marker profiling for appropriate treatment and management of HBV and HCV infections as well as potential therapeutic targets. From the clinical aspect, significant literature gaps are filled with biomarker-based studies contributing more to the existing literature and the findings for further studies.